Medical Device and Diagnostics
News & Jobs
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login  
Medical Device Companies | Diagnostic Companies | Organizations | Search Profiles
 Company Profile


The Medicines Company 

8 Sylvan Way

Parsippany  New Jersey  07054  U.S.A.
Phone: 973-290-6000 Fax: 973-656-9898


The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.

 Key Statistics

Ownership: Public

Web Site: The Medicines Company
Employees: 500+
Symbol: MDCO


UCB, Inc.  Contract manufacturing of Bivalirudin peptide active ingredient


 Company News
The Medicines Company (MDCO) To Announce First Quarter Financial Results On Tuesday, May 5, 2015 4/21/2015 11:38:29 AM
The Medicines Company (MDCO) Release: FDA Approves New Formulation Of MINOCIN (Minocycline) For Injection 4/20/2015 11:17:38 AM
FDA Advisory Committee Recommends Approval Of The Medicines Company (MDCO)'s Antiplatelet Therapy Cangrelor 4/16/2015 5:58:15 AM
The Medicines Company (MDCO) Surges as FDA Panel Approves Once-Rejected Blood Clot Preventer 4/16/2015 5:55:56 AM
The Medicines Company (MDCO)’s Kengreal Gets FDA Support After Previous Setbacks 4/13/2015 7:34:13 AM
The Medicines Company (MDCO) Announces Preliminary Worldwide Net Revenue For The First Quarter Of 2015 4/10/2015 11:24:35 AM
The Medicines Company (MDCO) Settles Angiomax (Bivalirudin) Patent Litigation With Sun 4/1/2015 12:20:22 PM
The Medicines Company (MDCO) Receives European Commission (EC) Approval For Three Hospital Acute Care Products: KENGREXAL (Cangrelor), ORBACTIV (Oritavancin) And RAPLIXA(Sealant Powder) 3/30/2015 12:41:14 PM
The Medicines Company (MDCO) Release: Independent Research Confirms Reduction In Mortality And Bleeding Associated With Bivalirudin In High-Risk Acute Coronary Syndrome Patients Undergoing PCI 3/17/2015 11:19:22 AM
The Medicines Company (MDCO) Announces Participation At 2015 American College of Cardiology Scientific Sessions In San Diego 3/11/2015 10:39:36 AM